Innovative Biotech Focus NovaBiotics operates in the cutting-edge biotechnology segment with dual divisions addressing both consumer health and advanced clinical-stage therapeutics, creating opportunities for partnerships in personal care and life sciences markets.

Funding and Growth With recent investments from Innovate UK and UKRI totaling over $3 million, NovaBiotics demonstrates robust financial backing that can support clinical development, collaborations, and market expansion initiatives.

Expanding Leadership The appointment of experienced non-executive directors, including Trevor Phillips and Malcolm Barratt-Johnson, signals strategic growth and a strengthened governance structure, facilitating investor and partner confidence.

Regulatory and Clinical Progress NovaBiotics' ongoing development of immune-based therapies like Nylexa and their clinical trial activities in infectious diseases present opportunities for healthcare partners and distributors looking for innovative treatments.

Market Potential Targeting global markets with significant unmet needs in inflammatory and infectious diseases, combined with consumer health products, positions NovaBiotics as a versatile partner for companies seeking to expand their portfolio into biotech and healthcare sectors.